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Abstract
AIM
To explore the role of killer immunoglobulin receptor 
(KIR ) genes in responsiveness or non-responsiveness 
to vaccination against hepatitis B virus.
METHODS
We recruited 101 voluntary participants between 
March 2010 and December 2011. Sera samples from 
vaccinated and non-vaccinated participants were tested 
for the presence of anti-HBs antibodies as a measure 
of protection against hepatitis B, hepatitis B surface 
antigen and hepatitis B core antibody as indicators of 
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infection by enzyme-linked immunosorbent assay. KIR 
gene frequencies were determined by polymerase chain 
reaction.
RESULTS
Sera samples from 99 participants were tested for the 
levels of anti-HBs as an indicator of protection (≥ 10 
mIU/ml) following vaccination as defined by the World 
Health Organization international reference standard. 
Among the vaccinated participants, 47% (35/74) had 
anti-HBs titers above 100 mIU/ml, 22% (16/74) had anti-
HBs ranging between 10-100 mIU/ml, and 20% (15/74) 
had values of less than 10 mIU/ml. We report the lack 
of significant association between the number of vaccine 
dosages and the titer of antibodies among our vaccinated 
participants. The inhibitory KIR2Dl1, KIR2Dl4, KIR3Dl1, 
KIR3Dl2, and KIR3Dl were detected in more than 95%, 
whereas KIR2Dl2, KIR2Dl3, KIR2Dl5 (KR2Dl5A and 
KIR2Dl5B) were expressed in 56%, 84% and 42% (25% 
and 29%) of participants, respectively. The observed 
frequency of the activating KIR genes ranged between 
35% and 55% except for KIR2DS4, detected in 95% of 
the study participants (40.6% 2DS4*001/002; 82.2% 
2DS4*003/007). KIR2DP1 pseudogene was detected in 
99% of our participants, whereas KIR3DP*001/02/04 
and KIR3DP1*003 had frequencies of 17% and 100%, 
respectively. No association between the frequency of 
KIR genes and anti-HBs antibodies was detected. When 
we compared the frequency of KIR  genes between 
vaccinated individuals with protective antibodies titers 
and those who lost their protective antibody levels, 
we did not detect a significant difference. KIR2Dl5B 
was significantly different among different groups of 
vaccinated participants (group Ⅰ > 100 mIU/ml, group 
Ⅱ 10-100 mIU/ml, group Ⅲ < 10 mIU/ml and group Ⅳ 
with undetectable levels of protective antibodies). 
CONCLUSION
To our knowledge, this is the first study screening for the 
possible role of KIR genes among individuals vaccinated 
against hepatitis B virus (HBV). Our results can be used 
to design larger studies to better understand the role of 
KIR genes in protection against or susceptibility to HBV 
post vaccination.
Key words: Hepatitis B virus; Killer immunoglobulin 
receptors; Hepatitis B vaccine; lebanon; Natural killer 
cells
© The Author(s) 2016. Published by Baishideng Publishing 
Group Inc. All rights reserved.
Core tip: Currently, there are no data supporting the use 
of booster doses of hepatitis B vaccine among immuno-
competent individuals responding to a complete primary 
vaccination regimen. Importantly, 5%-10% of healthy 
adults do not generate protective levels of antibodies 
and are hence considered non-responders. This study 
aims to explore the role of killer immunoglobulin re-
ceptor genes in responsiveness or non-responsiveness 
to vaccination against hepatitis B virus.
Melhem NM, Mahfouz RA, Kreidieh K, Abdul-Khalik R, El-
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vaccinated against hepatitis B virus in Lebanon. World J Hepatol 
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INTRODUCTION
Infection with hepatitis B virus (HBV) results in a spec­
trum of clinical outcomes ranging from acute hepatitis to 
end­stage liver disease and hepatocellular carcinoma[1] 
with an estimated lifetime risk of 25%­40%[2]. Booster 
studies suggest that memory begins to decline 15 years 
following vaccination among adolescents vaccinated 
in infancy[3­6]. Other studies suggest the persistence of 
immune memory for 20 years or longer[7­9]. Currently, 
there are no data supporting the use of booster doses 
of hepatitis B vaccine among immuno­competent indivi­
duals responding to a complete primary vaccination 
regimen (3 doses). Importantly, 5%­10% of healthy 
adults do not generate protective levels of antibodies and 
are hence considered non­responders[10]. Consequently, 
long­term protection is still debatable[11] and not linked to 
genetic factors.
Natural killer (NK) cells are known to induce antiviral 
and antitumor immunity via production of pro-inflammatory 
cytokines and lysis of infected or transformed cells[12]. Killer 
immunoglobulin receptor (KIR) genes encode receptors 
expressed on NK cells. Based on the gene content, two 
groups of KIR haplotypes are known in humans: A and 
B. Haplotype A encodes inhibitory receptors and consists 
of nine genes (3DL3, 2DL3, 2DP1, 2DL1, 3DP1, 2DL4, 
3DL1, one activating (2DS4), 3DL2, and 2DL5) whereas 
haplotype B carries a variety of gene combinations 
and encodes more activating receptors as compared 
to haplotype A (3DL3, 2DS2, 2DL2, 2DL5B (inhibitory) 
2DS3, 2DP1, 2DL1, 3DP1, 2DL4, 3DS1, 2DL5A (inhibitory), 
2DS5, 2DS1, and 3DL2)[13].
KIR3DS1­ and KIR3DL1­expressing NK cells were 
reported to expand in acute and chronic human immu­
nodeficiency virus (HIV)­1 infection, respectively[14]. 
Similarly, reports suggest that KIR2DL2 and/or KIR2DL3 
along with their ligand human leukocyte antigen (HLA)­C1 
are associated with severe influenza infection; in addition, 
the frequency of KIR3DS1, KIR2DS5 and KIR2DL5 was 
also related to the severity of the disease[15]. KIR2DS2 
and KIR2DS3 were found to be associated with suscepti­
bility to chronic hepatitis B infection, whereas KIR2DS1, 
KIR3DS1 and KIR2DL5 may act as protective genes 
leading to viral clearance among the Chinese Han 
population[16]. A difference between the frequency of 
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different KIR haplotypes among chronically infected 
individuals and those spontaneously recovering from HBV 
infection was also demonstrated in this population[17]. 
Recently, the rates of KIR2DL3 and 3DS1 were reported 
to be higher in healthy Turkish individuals as compared 
to patients with chronic HBV and those with spontaneous 
remission[18]; authors suggested the possible role of these 
genes in protection against HBV infection. In addition, 
genetic factors have been reported to play a role in the 
regulation of post­vaccine immune responses[19]. This 
was observed with antibody responses to a number of 
vaccine antigens including hepatitis B.
It is clear that the interaction between KIRs and their 
corresponding HLA ligands is implicated in differential 
responses to HIV, hepatitis C virus (HCV) and HBV as 
well as other disease conditions[20­23]. Immune responses, 
like many biological responses, are characterized by a 
wide range of variation between individuals. This has 
been described following natural infection or in response 
to vaccination[24]. HLA, cytokines, toll­like receptors 
and related gene variants have been associated with 
a variety of immune responses following vaccinations. 
Recently, single­nucleotide polymorphism associations 
were described to be involved in innate and adaptive 
immune response regulation following measles and 
rubella vaccinations[25,26]. Similarly, a difference in gene 
expression was also reported between high and low 
responders to smallpox vaccine[27]. The fact that antibody 
response to hepatitis B vaccine is non­protective in up to 
10% of individuals[10], and that a genetic basis to non­
responsiveness is reported[19,24], prompted us to explore 
the role of KIR genes in response to hepatitis B vaccine in 
a cohort of healthy vaccinated Lebanese adults. 
MATERIALS AND METHODS
Study participants and samples
Human subject approval was obtained for this study 
from the institutional review board of the American 
University of Beirut and all the methods were carried 
out in accordance with the approved ethical guidelines. 
A written informed consent was signed by the study 
subjects before participation in the study. A data collec­
tion form was administered to the study participants (≥ 
18 years old) to collect demographic information, data 
related to exposure and risk behavior information. One 
hundred and one subjects were recruited during the 
time period March 2010­December 2011. Subjects were 
excluded if they had a prior or current history of HCV, 
HIV­1, renal disease or cancer. Children or adolescents of 
HBV carrier mothers and vaccinated in infancy were not 
included in the study. Blood was drawn from the study 
participants and peripheral blood mononuclear cells[28] 
and sera were collected and stored in liquid nitrogen and 
at ­80 ℃, respectively. DNA was extracted from whole 
blood of the study participants using the QIAamp DNA 
Blood Midikit (Qiagen, Germany), as per manufacturer’s 
instructions. The integrity of the purified DNA was checked 
by gel electrophoresis and storage was at ­20 ℃. 
Enzyme-linked immunosorbent assay
While we recruited 101 voluntary participants, sera sam­
ples of 99 HBV vaccinated and non­vaccinated study 
participants were tested in duplicate for the presence of 
anti­HBs antibodies as a measure of protection against 
hepatitis B, hepatitis B surface antigen (HBsAg) and 
hepatitis B core antibody (anti­HBc) as indicators of 
infection. We did not have enough sera to use in the 
analysis for two of our study participants. The Monolisa 
HBsAg ULTRA, anti­HBs PLUS and anti­HBc PLUS assays 
(BIO­RAD, France) were used as per manufacturer’s in­
structions, respectively. Anti­HBs antibodies were measured 
in mIU/mL and levels ≥ 10 mIU/mL were indicative of 
post­vaccination protection[29,30]. 
KIR genotyping
The polymerase chain reaction (PCR)­based KIR geno­
typing SSP Kit (Invitrogen, Brown Deer, WI, United 
States) was used to detect the presence and absence of 
KIR genes, as per manufacturer’s instructions. Briefly, 25 
µL of DNA was used along with the primer sets to amplify 
the alleles described by the World Health Organization 
(WHO) international nomenclature committee (http://
www.ebi.ac.uk/ipd/kir/). All amplifications were performed 
using PX2 thermocycler (ThermoHybrid, United Kingdom) 
programmed with a 1­min denaturation step at 95 ℃, 
followed by 30 cycles of 94 ℃ for 20 s, 63 ℃ for 20 s, 
and 72 ℃ for 90 s and finally 4 ℃ in the thermal cycler. 
PCR products were gel-purified and visualized under UV 
transillumination (Sigma, California, United States)[31]. 
The presence and absence of the following gene loci and 
variants were tested: 2DL1, 2DL2, 2DL3, 2DL4, 2DL5A, 
2DL5B, 2DS1, 2DS2, 2DS3, 2DS5, 3DL1, 3DL2, 3DL3, 
3DS1, 2DP1, and 3DP1. The variants of the KIR3DP1 
pseudogene, KIR3DP*001/002/004 and KIR3DP1*003 
were also detected in addition to KIR2DS4 variants: 
2DS4*001/002 and 2DS4*003/007. The frequency 
of KIR was calculated by direct count of the observed 
phenotype and referred to as observed frequency (OF). 
In addition, the estimated KIR gene frequency (KF) 
for the putative loci was calculated using the following 
formula: KF = 1 - √ (1-OF) based on the assumption 
of Hardy­Weinberg equilibrium[32]. The frequencies of 
haplotype A and B were calculated using the following 
formula: haplotype A = (2nAA + nAB)/2n and haplotype B 
= (2nBB + nAB)/2n, where nAA, nAB and nBB are the numbers 
of individuals with haplotype group AA, AB and BB, 
respectively and n is the total number of individuals[33].
Statistical analysis
SPSS 19 was used for statistical analyses. We compared 
vaccinated and non­vaccinated subjects for each of the 
KIR polymorphisms using χ2 and Fisher­exact test (FET) 
and reported the odds ratio and 95%CI. Similar analyses 
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were conducted for the comparison of protected and 
non­protected subjects within the vaccinated group. We 
also examined the relationship between genotypes and 
the presence or absence of KIR genes and the levels of 
anti­HBs and KIR genes among the vaccinated subjects 
using χ2 and FET; for these comparisons, post-hoc tests 
were conducted only if the omnibus test was significant. 
We corrected for multiple comparisons for post­hoc tests 
using Bonferroni correction.
RESULTS
Characteristics of study participants
One hundred and one subjects were recruited between 
March 2010 and December 2011; 39% of the study 
participants were males and 61% were females. The 
majority of our study participants were 19­29 years old 
(40%). Table 1 summarizes the characteristics of the 
study participants. The majority (75%) held a university 
undergraduate degree or higher and was employed. 
During recruitment and when participants were asked 
about their vaccine status, 50% of our voluntary par­
ticipants self­reported that they were vaccinated against 
HBV whereas 25% thought they were not vaccinated 
and 26% did not know their vaccine status. 
In an attempt to confirm the vaccination status of 
our study participants, sera samples from 99 participants 
were tested for the levels of anti­HBs as an indicator 
of protection (≥ 10 mIU/mL) as defined by the WHO 
international reference standard[30,34]. This is especially 
due to the lack of documented dosages of hepatitis B 
vaccine for many of the study participants as well as lack 
of knowledge of the vaccination status of many of the 
study participants. In the subsequent analyses, data on 
these 99 voluntary subjects are reported; participants 
with anti­HBs antibodies ≥ 10 mIU/mL will be con­
sidered vaccinated against hepatitis B. We also tested 
the sera samples for anti­HBc as a marker of previous 
infection and for HBsAg, a marker associated with recent 
exposure to HBV. All our participants were negative 
for HBsAg. Among the voluntary participants, 74/99 
(75%) were vaccinated against hepatitis B as judged by 
the detection of anti-HBs titers; whereas 25% (25/99) 
were classified as non­vaccinated against hepatitis B. 
Among the vaccinated participants, 47% (35/74) had 
anti­HBs titers above 100 mIU/mL, 22% (16/74) had 
anti­HBs ranging between 10­100 mIU/mL, and 20% 
(15/74) had values of less than 10 mIU/mL. The time of 
vaccination (when available) ranged between the years 
1999 and 2011, with some participants receiving 2 doses 
and others receiving 3 or more doses. When we tested 
for an association between the age groups of our study 
participants (19­29, 30­39, 40­49, 50­59, 60­69, 70­79 
and 80­89) and the concentration of anti­HBs antibodies 
among vaccinated subjects, a p value of 0.047 was 
detected (FET). Nine percent (7/74) of the vaccinated 
participants had undetectable levels of protective anti­
bodies. Five out of 7 (71%) of the former group were 
health-care workers; the latter are expected to be 
continuously monitored for protection against HBV due 
to the nature of their work. Importantly, anti­HBc was 
positive in 3% (3/99) of our study participants presenting 
with anti­HBs levels ranging between 110­1000 mIU/mL. 
This is associated with protection as a result of natural 
infection. One of these participants is a vaccinated female 
nurse, whereas the other 2 are non­vaccinated and are 
not in the health care profession. None of the anti­HBc 
positive participants were HBsAg positive. 
KIR genotypes and genes frequencies
We next determined the KIR genotypes among the 
study participants: 44%, 40% and 16% were carriers 
of AA, AB and BB genotypes, respectively, with a 1.77 
A to B ratio. The genotype was classified as B if any of 
the following genes was detected: 2DL2, 2DL5, 3DS1, 
2DS1, 2DS2, 2DS3 and 2DS5. If none of these was 
detected, the genotype was considered as AA. Similarly, 
if none of the A haplotypes was detected, the genotype 
was classified as BB; 77%, 75% and 69% of the AA, 
AB and BB carriers were vaccinated, respectively. There 
was no significant difference between the expression of 
AA, AB and BB among vaccinated and non­vaccinated 
participants (FET, p = 0.784). Similarly, we did not 
detect any significant difference when we compared the 
frequencies of KIR genotypes among the vaccinated 
with anti­HBs levels less than 10, 10­100 and above 
100 mIU/mL. We did not detect any difference between 
the frequencies of KIR genotypes among vaccinated 
participants with protective and non­protective levels of 
anti­HBs (FET, p = 0.865). 
n %
Gender (n = 101)
   Male 39  38.6
   Female 62  61.4
Age (yr) (n = 95)
   19-29 38  40.0
   30-39 19  20.0
   40-49 17  17.9
   50-59 11  11.6
   60-69   6    6.3
   70-79   2    2.1
   80-89   2    2.1
Education (n = 99)
   Illiterate   3    3.0
   Primary School Education   3    3.0
   Secondary School Graduate   9    9.1
   High School Education 10  10.1
   University Undergraduate Level 50  50.5
   Others 24  24.2
Occupation (n = 99)
   Student 15  15.2
   Employed 74  74.7
   Unemployed   7    7.1
   Retired   3 3
Table 1  Demographics and characteristics of participants
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We divided the KIR genes expressed in our study 
participants into inhibitory, non­inhibitory (or activating) 
and those encoding inhibitory and activating signals, 
as previously described[13]. The inhibitory KIR2DL1, 
KIR2DL4, KIR3DL1, KIR3DL2, and KIR3DL were detected 
in more than 95%, whereas KIR2DL2, KIR2DL3, 
KIR2DL5 (KR2DL5A and KIR2DL5B) were expressed in 
56%, 84% and 42% (25% and 29%) of participants, 
respectively (Table 2). The OF of the activating KIR genes 
ranged between 35% and 55% except for KIR2DS4, 
detected in 95% of the study participants (40.6% 
2DS4*001/002; 82.2% 2DS4*003/007). KIR2DP1 pseu-
dogene was detected in 99% of our participants, whereas 
KIR3DP*001/02/04 and KIR3DP1*003 had frequencies 
of 17% and 100%, respectively. The corresponding 
estimated frequencies of each KIR gene followed the 
same trend or order as the OF data.
For this analysis and thereafter, we studied the 
genes with enough variability, particularly 2DL2, 2DL3, 
2DL5 (2DL5A, 2DL5B), 2DS1, 2DS2, 2DS3, 2DS4 
(and its variants), 2DS5, 3DS1 and the pseudogene 
3DP1*001/002/004 (Table 2). We report the lack of 
significant difference in the frequency of KIR genes 
among vaccinated and non­vaccinated participants 
(Table 3). Moreover, there was no significant difference 
in the frequency of these genes among participants 
protected against HBV and those that are not protected 
against HBV, as judged by their level of anti­HBs 
antibodies (Table 4).
We performed similar analyses to determine the 
relationship between AA, AB, BB genotypes and the 
expression of KIR genes showing enough variability 
(Table 5). 2DL2 (χ2, p = 0.00), 2DL3 (χ2, p = 0.00), 
2DS2 (χ2, p = 0.00), 2DS3 (χ2, p = 0.00), 2DL5B FET (p 
= 0.00), and 3DP1001/002/004 (FET, p = 0.006) were 
found to be significantly different between genotypes 
but not 2DS1 (χ2, p = 0.749), 2DL5A (FET, p = 0.782), 
2DS4*001/002 (χ2, p = 0.621), 2DS4*003/007 (FET, 
p = 0.392) and 3DS1 (χ2, p = 0.948). For those genes 
showing significant differences among the AA, AB and BB 
genotypes, we computed post­hoc comparisons. These 
differences still hold significance between subgroups 
except for 2DL5B, 2DS2, 2DS3 and 3DP1*001/002/004 
between genotypes AB and BB. 
KIR gene frequencies among vaccinated and non-
vaccinated participants
To evaluate the role of KIR genes in protection against 
or susceptibility to HBV, we next compared the fre­
quency of KIR genes among HBV­vaccinated and non­
vaccinated participants (as judged by the level of anti­
HBs antibodies). Depending on their anti­HBs levels 
that we tested for in this study, participants vaccinated 
against hepatitis B were divided into 4 groups: Group Ⅰ > 
KIR genes Anti-HBsAg < 10 mIU/mL (n  = 22) Anti-HBsAg ≥ 10 mIU/mL (n  = 52) Test1 OR (95%CI) P  value
2DL2 14 (63.60) 27 (51.90) 0.858 0.62 (0.22-1.72)     0.446
2DL3 18 (81.80) 45 (86.40) FET 1.43 (0.37-5.48)     0.723
2DL5A   8 (36.40) 13 (25.00) 0.982 0.58 (0.20-1.70) 0.4
2DL5B   5 (22.70) 19 (36.50) 1.346 1.97 (0.62-6.16)     0.289
2DS1 11 (50.00) 19 (36.50) 1.162 0.58 (0.21-1.58)   0.31
2DS2 14 (63.60) 26 (50.00) 1.157 0.57 (0.21-1.59)     0.318
2DS3   9 (40.90) 23 (44.20) 0.069 1.15 (0.42-3.15)     0.804
2DS4*001/002   8 (36.40) 20 (38.40) 0.029   1.09 (0.39-3.072)   1.00
2DS4*003/007 19 (86.40) 41 (78.85) FET 0.59 (0.15-2.36)     0.534
2DS5 10 (45.50) 17 (32.60) 1.087 0.58 (0.21-1.62)     0.428
3DS1 11 (50.00) 21 (40.40) 0.582 0.68 (0.25-1.85)     0.608
3DP*001/002/004   6 (27.30)   9 (17.30) FET 0.56 (0.17-1.82)     0.355
Table 3  Killer immunoglobulin receptor gene frequencies among study participants vaccinated against hepatitis B virus (protected 
and non-protected by hepatitis B vaccine)  n  (%)
1The statistical test performed to compare the frequencies of KIR gene expression among vaccinated and non-vaccinated study participants where by FET 
refers to Fisher’s exact test and the rest of the values represent the Pearson χ 2 value. We compared the frequencies of KIR genes with enough variability 
between study participants that were vaccinated against hepatitis B virus. The vaccinated participants were divided for this analysis into 2 groups 
depending on the level of anti-HBsAg. Anti-HBsAg < 10 mIU/mL, not protected against hepatitis B virus infection; anti-HBsAg ≥ 10 mIU/mL, protected 
against hepatitis B virus infection as a result of vaccination. KIR: Killer immunoglobulin receptor; FET: Fisher-exact test; HBsAg: Hepatitis B surface 
antigen. OR: Odds ratio.
Inhibitory KIR Non-inhibitory KIR Pseudogene
2DL1 2DL2 2DL3 2DL4 2DL5 3DL1 3DL2 3DL3 2DS1 2DS2 2DS3 2DS4 2DS5 3DS1 2DP1 3DP*001/002/004 3DP1*003
OF 99 56 84 100 42 96 100 100 40.6 55.4 46.5 95 34.7 41.6 99 17 100
KLF 0.9 0.34 0.6     1 0.24 0.8     1     1 0.23 0.33 0.27 0.78 0.19 0.24 0.9   1     1
2DL5A, 24.8%; 2DL5B, 28.7%; 2DS4*001/*002, 40.6%; 2DS4*003/007, 82.2%. KIR: Killer immunoglobulin receptor; OF: Observed frequency calculated by 
direct counting; KLF: Gene frequency calculated using the formula 1 - √ (1 - OF).
Table 2  The observed and estimated killer immunoglobulin receptor gene frequencies in the study participants
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100 mIU/mL, group Ⅱ 10­100 mIU/mL, group Ⅲ < 
10 mIU/mL and group Ⅳ with undetectable levels of 
protective antibodies. The frequency of only KIR2DL5B 
was significantly different among these categories (FET, 
p = 0.0263) (Table 6). When we performed post­hoc 
comparisons between these groups, we detected no 
significant difference in the expression of KIR2DL5B. 
These groups of vaccinated participants were also similar 
in relation to the expression of AA, AB and BB genotypes 
(FET, p = 0.669). 
We identified 3 participants testing positive for anti-
HBc with anti­HBs levels higher than 100 mIU/mL. Two 
out of three of these participants were non­vaccinated 
and thus we believe they are protected as a result of 
natural infection. The third participant was vaccinated 
against HBV. Two out of three (66.7%) of these par­
ticipants carry the AB genotype and one participant is 
AA positive. The three participants expressed 2DL1, 
2DL3, 3DL1, 3DL2, 3DL3 (inhibitory), activating genes 
(2DS3, 2DS4*001/002 variant) and both inhibitory and 
activating genes (2DL4, 2DP1 and 3DP1*003). These 
subjects did not express 2DL5A or 3DP1*001/002/004. 
We did not test for the presence of HBV DNA among 
these participants. We did not find any significant relation-
ship between the genotype of these participants and the 
expression of KIR genes, or between the KIR genes and 
the susceptibility to natural or breakthrough infection.
DISCUSSION
The administration of hepatitis B vaccine in infancy 
is 95% effective and correlates with long­term pro­
tection[8,35,36]. However, vaccine failure has been reported 
in 5% of hepatitis B-vaccinated persons; moreover, 
breakthrough infection has also been reported following 
vaccination with hepatitis B vaccine[37]. The increase 
KIR genes Vaccinated (n  = 74) Non-vaccinated (n  = 25) Test1 OR (95%CI) P  value
2DL2 41 (55.40) 15 (60.00) 0.161   0.83 (0.33-2.082)   0.436
2DL3 63 (85.10) 20 (80.00) 0.364 1.43 (0.44-4.62)   0.374
2DL5A 21 (28.40)   4 (16.00) 1.517 2.08 (0.64-6.79)   0.168
2DL5B 24 (32.40)   5 (20.00) 1.395 1.92 (0.64-5.73)   0.178
2DS1 30 (40.50) 10 (40.00) 0.002 1.02 (0.41-2.58)   0.577
2DS2 40 (54.10) 15 (60.00) 0.268 0.78 (0.31-1.97) 0.39
2DS3 32 (43.20) 14 (56.00) 1.223 0.60 (0.24-1.49)   0.191
2DS4*001/002 28 (37.80) 11 (44.00) 0.297 0.77 (0.31-1.94)   0.376
2DS4*003/007 60 (81.10) 22 (88.00) FET 0.58 (0.15-2.23)   0.324
2DS5 27 (36.50)   7 (28.00) 0.597 1.47 (0.55-3.99)   0.302
3DS1 32 (43.20)   9 (36.00) 0.246 1.35 (0.53-3.46)   0.401
3DP*001/002/004 15 (20.30) 2 (8.00) FET   2.92 (1.62-13.80)   0.134
Table 4  Killer immunoglobulin receptor gene frequencies among study participants vaccinated against hepatitis B virus as compared 
to non-vaccinated subjects  n  (%)
We compared the frequencies of KIR genes with enough variability between study participants that were vaccinated against hepatitis B virus and those 
that were not. 1The statistical test performed to compare the frequencies of KIR gene expression among vaccinated and non-vaccinated study participants 
whereby FET refers to Fisher’s exact test and the rest of the values represent the Pearson χ 2 value. KIR: Killer immunoglobulin receptor; FET: Fisher-exact 
test; OR: Odds ratio.
KIR genes AA (n  = 44) AB (n  = 41) BB (n  = 16) Test1 P  value
2DL2 0 (0.00)   41 (100.00)   16 (100.00) 101 0.00a
2DL3   44 (100.00)   41 (100.00) 0 (0.00) 101 0.00a
2DL5A 10 (22.70) 10 (22.70)   5 (31.25) FET  0.782
2DL5B 1 (2.27) 20 (24.39)   8 (50.00) FET 0.00a
2DS1 16 (36.30) 18 (43.90)   7 (43.75) 0.579  0.749
2DS2 0 (0.00) 40 (97.50)   16 (100.00)   97.051 0.00a
2DS3 3 (6.80) 30 (73.17) 14 (87.50) 50.38 0.00a
2DS4*001/002 16 (36.40) 19 (37.50)   6 (37.50)     0.952  0.621
2DS4*003/007 38 (86.40) 31 (75.60) 14 (87.50) FET  0.392
2DS5 14 (31.80) 16 (39.00)   5 (31.30)     0.584  0.747
3DS1 18 (40.90) 18 (43.90)   6 (40.00)     0.107  0.948
3DP*001/002/004 2 (4.50) 10 (24.40)   5 (31.30) FET     0.0006a
Table 5  The relationship between AA, AB and BB genotypes and the expression of 
killer immunoglobulin receptor genes among the study participants  n  (%)
1The statistical test performed to determine the relationship between AA, AB and BB genotypes and 
the expression of KIR genes among vaccinated and non-vaccinated study participants. FET refers to 
the Fisher’s exact test and the rest of the values represent the Pearson χ 2 value. aP < 0.05, significant. 
KIR: Killer immunoglobulin receptor; FET: Fisher-exact test.
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in circulating NK cells, major players in the innate 
immune system and regulators of the virus­specific T 
cell responses through their cross­talk with dendritic 
cells and T cells[38­40], was suggested to contribute to 
HBV viral control[41]. The impact of genetic regulation 
on immune responses following vaccinations has been 
previously reported[19,24]. This evidence prompted us to 
explore the potential role of KIR following hepatitis B 
vaccination. In Lebanon, hepatitis B vaccine is offered 
as part of the immunization program early in childhood 
as per the WHO guidelines. In this study, 69% of the 
vaccinated participants retained more than 10 mIU/mL 
of anti­HBs antibodies and hence are immune to HBV 
infection; whereas 30% are susceptible to the latter 
due to either undetectable levels of antibodies or levels 
below 10 mIU/mL. We do not have data on the time of 
vaccination of these participants to reflect on the duration 
of the retention or the loss of the immune response post­
vaccination. We report the lack of significant association 
between the number of vaccine dosages (when vaccine 
dosage is available) and the titer of antibodies among 
vaccinated participants. Recent reports show that 
multiple immunizations against hepatitis B are inefficient 
at mounting antibody responses[42], while others suggest 
that immunization against hepatitis in infancy is asso-
ciated with a seroprotective response to a challenge 
dose of vaccine with extended duration of protection 
through adolescent years[43]. We cannot suggest similar 
trends from our results due to the lack of data on the 
time of vaccination, the age at vaccination, as well as the 
number of dosages administered for many participants.
Anti­HBc antibodies, indicators of HBV infection, 
were detected in 3 participants (3%) in the absence 
of HBsAg, with one being a nurse suspected of being 
exposed to HBV at the work place. This might suggest a 
“breakthrough” infection occurring following vaccination 
against hepatitis B; this is suggested since health care 
workers are regularly monitored for protective levels of 
anti­HBs antibodies. However, due to the lack of data 
on the timing of vaccination and/or infection of this par­
ticipant, we cannot confirm whether exposure to HBV 
has occurred before or after vaccination. The other 2 
participants are non­vaccinated and are protected with 
high levels of anti­HBs antibodies as a result of natural 
infection. We do not have data pertaining to the time 
of infection following vaccination; moreover, we did not 
perform HBV DNA testing. Health care workers with 
undetectable anti­HBsAg levels detected in our study are 
clearly susceptible to HBV infection and consequently 
in need of booster vaccination to induce an anamnestic 
response in order to prevent acute disease and carrier 
state. 
While hepatitis B vaccine booster doses are not 
currently recommended following vaccination, a better 
understanding of the correlates of long­term immunity 
is needed. This is critical especially since several studies 
show that vaccines with anti­HBs levels of 10­99 mIU/
mL achieved following primary vaccination are less 
likely to produce an anamnestic response following a 
booster HBV vaccine as compared to those with anti­
HBs ≥ 100 mIU/mL[35,44]. NK cells play a major role in 
the innate immune system as first line of defense and 
in the regulation of the virus­specific T cell responses 
through their cross­talk with dendritic cells and T 
cells[38­40]. Moreover, NK cells are suggested to contribute 
to HBV control[41]. Our data show that genotypes with 
11 KIR genes were most prevalent, with AA genotype 
being more frequent among the study participants. The 
inhibitory KIR genes were more frequent among our 
study participants than the activating genes, which is in 
agreement with a finding associated with A haplotype 
being present in higher numbers in inhibitory KIR genes[39].
KIR2DL4, KIR3DL2, KIR3DL3 and KIR3DP1*003 were 
present in every participant. This is expected since these 
KIR genes Group I1 (n  = 36) Group Ⅱ2 (n  = 16) Group Ⅲ3 (n  = 15) Group Ⅳ4 (n  = 7) Test5 P  value
2DL2 17 (47.20) 10 (62.50) 11 (73.30) 3 (42.90) FET 0.362
2DL3 31 (86.10) 14 (87.50) 12 (80.00) 6 (85.70) FET 0.824
2DL5A   9 (25.00)   4 (25.00)   4 (26.70) 4 (57.10) FET 0.987
2DL5B   9 (25.00) 10 (62.50)   4 (26.70) 1 (14.30) FET  0.0236
2DS1 11 (30.60)   8 (50.00)   7 (46.70) 4 (57.10) FET 0.530
2DS2 16 (44.40) 10 (62.50) 11 (73.30) 3 (42.90) FET 0.270
2DS3 12 (33.30) 11 (68.80)   8 (53.30) 1 (14.30) 5.01 0.060
2DS4*001/002 15 (41.70)   5 (31.30)   6 (40.00) 2 (28.60)   0.568 0.920
2DS4*003/007 28 (77.80) 13 (81.30) 13 (86.70) 6 (85.70) FET 0.860
2DS5 11 (30.60)   6 (37.50)   6 (40.00) 3 (42.90)   0.846 0.850
3DS1 14 (38.90)   7 (43.80)   7 (46.70) 6 (85.70) FET 0.960
2DL4   36 (100.00)   16 (100.00)   15 (100.00) 4 (57.10)   0.258 0.970
3DP*001/002/004   8 (22.20) 1 (6.30)   4 (26.70) 1 (14.30) FET 0.420
Table 6  Killer immunoglobulin receptor gene expression and levels of anti-HBs among the vaccinated study participants  n  (%)
1Group Ⅰ: Vaccinated participants and anti-HBs titers > 100 mIU/mL; 2Group Ⅱ: Vaccinated participants and anti-HBs titers 10-100 mIU/mL; 3Group 
Ⅲ: Vaccinated participants and anti-HBs titers 0.1-9.99 mIU/mL; 4Group Ⅳ: Vaccinated participants and anti-HBs titers = 0 mIU/mL; 5The statistical test 
performed to compare the frequencies of KIR gene expression among the vaccinated study participants whereby FET refers to Fisher’s exact test and the 
rest of the values represent the Pearson χ 2 value; 6Significant difference of KIR2DL5B expression among vaccinated study participants (P < 0.05). KIR: Killer 
immunoglobulin receptor; FET: Fisher-exact test.
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are framework genes. The frequency of KIR2DL5B is the 
only significantly different gene among the vaccinated 
participants with different anti­HBs antibodies titer. 
The role of KIR2DL5, expressed at frequencies ranging 
between 26% and 86% in all human populations, is not 
completely understood[45]. The ligand of KIR2DL5 is also 
still unknown.
A number of limitations exist, and these include the 
lack of data on the time of vaccination and corresponding 
age at time of vaccination of the study participants, and 
more importantly, the small sample size. Our sample 
size is powered to detect medium to large effect sizes 
when some of the effect sizes for group differences are 
small. However, medium to large effect sizes are those 
where group differences have more clinical significance, 
which we are powered to detect. Consequently, the clear 
impact that KIR genes have on susceptibility to acquiring 
hepatitis B or protection against the infection cannot be 
addressed in these small groups.
To our knowledge, this is the first study screening 
for the possible role of KIR genes among individuals 
vaccinated against HBV. While studies have shown the 
association between gene variants and immune responses 
to a variety of vaccines, little is known about the strength 
and the sustainability of antibody responses following 
vaccination against HBV in relation to expression of KIR 
genes. Our results are useful to design larger studies to 
better elucidate the role of KIR in susceptibility or long­
term protection against HBV as well as other diseases.
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